Stringent Complete Remission of Primary Plasma Cell Leukemia with Reduced-dose Bortezomib, Lenalidomide and Dexamethasone: A Case Report and Review of the Literature

Shuji Ueda; Masahiko Kubo; Noriko Matsuura; Hitomi Matsunaga; Seiko Kataoka; Tetsuo Maeda; Yoshiaki Inui; Sumio Kawata; Yuzuru Kanakura

doi:10.2169/internalmedicine.52.0001

CASE REPORTS

Stringent Complete Remission of Primary Plasma Cell Leukemia with Reduced-dose Bortezomib, Lenalidomide and Dexamethasone: A Case Report and Review of the Literature

Shuji Ueda, Masahiko Kubo, Noriko Matsuura, Hitomi Matsunaga, Seiko Kataoka, Tetsuo Maeda, Yoshiaki Inui, Sumio Kawata, Yuzuru Kanakura

Author information

Shuji Ueda
Department of Internal Medicine, Hyogo Prefectural Nishinomiya Hospital, Japan
Masahiko Kubo
Department of Internal Medicine, Hyogo Prefectural Nishinomiya Hospital, Japan
Noriko Matsuura
Department of Internal Medicine, Hyogo Prefectural Nishinomiya Hospital, Japan
Hitomi Matsunaga
Department of Internal Medicine, Hyogo Prefectural Nishinomiya Hospital, Japan
Seiko Kataoka
Department of Internal Medicine, Hyogo Prefectural Nishinomiya Hospital, Japan
Tetsuo Maeda
Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Japan
Yoshiaki Inui
Department of Internal Medicine, Hyogo Prefectural Nishinomiya Hospital, Japan
Sumio Kawata
Department of Internal Medicine, Hyogo Prefectural Nishinomiya Hospital, Japan
Yuzuru Kanakura
Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Japan

Keywords: plasma cell leukemia, stringent complete remission, reduced-dose VRd therapy

JOURNAL OPEN ACCESS

2013 Volume 52 Issue 11 Pages 1235-1238

DOI https://doi.org/10.2169/internalmedicine.52.0001

Details

Abstract

Plasma cell leukemia (PCL) is an aggressive variant of multiple myeloma characterized by a high level of plasma cells circulating in the peripheral blood. The prognosis of PCL patients treated with conventional chemotherapy remains poor. Some reports have suggested that both bortezomib and lenalidomide are effective in treating PCL. We herein report a case of primary PCL in which the patient achieved stringent complete remission after receiving combination chemotherapy with reduced-dose bortezomib, lenalidomide and dexamethasone (VRd). This regimen was very effective, and no severe adverse events were observed. A reduced-dose VRd regimen can be considered in PCL patients.

Corresponding author

Register with J-STAGE for free!